Nanjing Well Pharmaceutical Group Co (SHSE:603351) Net Income From Continuing Operations : ¥147 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Nanjing Well Pharmaceutical Group Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Nanjing Well Pharmaceutical Group Co's net income from continuing operations for the three months ended in Mar. 2025 was ¥36 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ¥147 Mil.

Nanjing Well Pharmaceutical Group Co Net Income From Continuing Operations Historical Data

The historical data trend for Nanjing Well Pharmaceutical Group Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Well Pharmaceutical Group Co Net Income From Continuing Operations Chart

Nanjing Well Pharmaceutical Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

100.45

100.15

94.43

109.12

145.21

Nanjing Well Pharmaceutical Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															33.52	44.20	33.32	34.18	35.77

Nanjing Well Pharmaceutical Group Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥147 Mil.

Nanjing Well Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Well Pharmaceutical Group Co Ltd (SHSE:603351) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 99, Changfeng Hexi Road, Nanjing Chemical Industry Park, Jiangsu Province, Nanjing, CHN, 210000

Website

http://www.well-js.com

Nanjing Well Pharmaceutical Group Co Ltd is engaged in research and development, production and sales of pharmaceutical auxiliary materials and synthetic lubricating base oil and other products. The company uses a variety of pharmaceutical dosage forms such as injection, oral administration and external use to guarantee the molding, effectiveness, stability and safety of pharmaceutical dosage forms.

Executives

Zou Jian Guo	senior management
Wang Fu Qiu	Directors, senior managers
Wu Rong Wen	Supervisors

Nanjing Well Pharmaceutical Group Co Headlines

No Headlines